argenx FIRST LOOK: Japanese nod on ITP
argenx obtains Japanese approval with IV Vyvgart for the treatment of ITP. Although the trial with SC Vyvgart recently did not demonstrate benefit (which led to scrapping of ITP filings in the US and EU), argenx could move forward with IV data alone in Japan, and has now gained regulators' nod. We anticipate Vyvgart to be mainly used in heavily pre-treated patients with ITP peak sales slightly north of € 100m, and mainly look forward to the upcoming CIDP approval and Phase 2 readouts in Sjogren's syndrome, PC-POTS and myositis. € 435 TP and Buy rating reiterated.Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.